Literature DB >> 28794047

No Substantial Evidence for Sexual Transmission of Minority HIV Drug Resistance Mutations in Men Who Have Sex with Men.

Antoine Chaillon1, Masato Nakazawa2, Joel O Wertheim2, Susan J Little2, Davey M Smith2,3, Sanjay R Mehta2,3, Sara Gianella2.   

Abstract

During primary HIV infection, the presence of minority drug resistance mutations (DRM) may be a consequence of sexual transmission, de novo mutations, or technical errors in identification. Baseline blood samples were collected from 24 HIV-infected antiretroviral-naive, genetically and epidemiologically linked source and recipient partners shortly after the recipient's estimated date of infection. An additional 32 longitudinal samples were available from 11 recipients. Deep sequencing of HIV reverse transcriptase (RT) was performed (Roche/454), and the sequences were screened for nucleoside and nonnucleoside RT inhibitor DRM. The likelihood of sexual transmission and persistence of DRM was assessed using Bayesian-based statistical modeling. While the majority of DRM (>20%) were consistently transmitted from source to recipient, the probability of detecting a minority DRM in the recipient was not increased when the same minority DRM was detected in the source (Bayes factor [BF] = 6.37). Longitudinal analyses revealed an exponential decay of DRM (BF = 0.05) while genetic diversity increased. Our analysis revealed no substantial evidence for sexual transmission of minority DRM (BF = 0.02). The presence of minority DRM during early infection, followed by a rapid decay, is consistent with the "mutation-selection balance" hypothesis, in which deleterious mutations are more efficiently purged later during HIV infection when the larger effective population size allows more efficient selection. Future studies using more recent sequencing technologies that are less prone to single-base errors should confirm these results by applying a similar Bayesian framework in other clinical settings.IMPORTANCE The advent of sensitive sequencing platforms has led to an increased identification of minority drug resistance mutations (DRM), including among antiretroviral therapy-naive HIV-infected individuals. While transmission of DRM may impact future therapy options for newly infected individuals, the clinical significance of the detection of minority DRM remains controversial. In the present study, we applied deep-sequencing techniques within a Bayesian hierarchical framework to a cohort of 24 transmission pairs to investigate whether minority DRM detected shortly after transmission were the consequence of (i) sexual transmission from the source, (ii) de novo emergence shortly after infection followed by viral selection and evolution, or (iii) technical errors/limitations of deep-sequencing methods. We found no clear evidence to support the sexual transmission of minority resistant variants, and our results suggested that minor resistant variants may emerge de novo shortly after transmission, when the small effective population size limits efficient purge by natural selection.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Bayesian hierarchical framework; deep sequencing; human immunodeficiency virus; minority drug resistance mutation; transmission

Mesh:

Substances:

Year:  2017        PMID: 28794047      PMCID: PMC5640831          DOI: 10.1128/JVI.00769-17

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  44 in total

1.  Datamonkey 2010: a suite of phylogenetic analysis tools for evolutionary biology.

Authors:  Wayne Delport; Art F Y Poon; Simon D W Frost; Sergei L Kosakovsky Pond
Journal:  Bioinformatics       Date:  2010-07-29       Impact factor: 6.937

2.  GARD: a genetic algorithm for recombination detection.

Authors:  Sergei L Kosakovsky Pond; David Posada; Michael B Gravenor; Christopher H Woelk; Simon D W Frost
Journal:  Bioinformatics       Date:  2006-11-16       Impact factor: 6.937

3.  Primer ID Informs Next-Generation Sequencing Platforms and Reveals Preexisting Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Coding Domain.

Authors:  Jessica R Keys; Shuntai Zhou; Jeffrey A Anderson; Joseph J Eron; Lauren A Rackoff; Cassandra Jabara; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2015-04-02       Impact factor: 2.205

4.  FUBAR: a fast, unconstrained bayesian approximation for inferring selection.

Authors:  Ben Murrell; Sasha Moola; Amandla Mabona; Thomas Weighill; Daniel Sheward; Sergei L Kosakovsky Pond; Konrad Scheffler
Journal:  Mol Biol Evol       Date:  2013-02-18       Impact factor: 16.240

5.  The origins of sexually transmitted HIV among men who have sex with men.

Authors:  David M Butler; Wayne Delport; Sergei L Kosakovsky Pond; Malcolm K Lakdawala; Pok Man Cheng; Susan J Little; Douglas D Richman; Davey M Smith
Journal:  Sci Transl Med       Date:  2010-02-10       Impact factor: 17.956

Review 6.  Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Authors:  K Van Vaerenbergh
Journal:  Verh K Acad Geneeskd Belg       Date:  2001

7.  Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome.

Authors:  Martin R Jakobsen; Martin Tolstrup; Ole S Søgaard; Louise B Jørgensen; Paul R Gorry; Alex Laursen; Lars Ostergaard
Journal:  Clin Infect Dis       Date:  2010-02-15       Impact factor: 9.079

8.  Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations.

Authors:  Grissell Tirado; Gloria Jove; Rakesh Kumar; Richard J Noel; Evelyn Reyes; Gladys Sepulveda; Y Yamamura; Anil Kumar
Journal:  Virology       Date:  2004-07-01       Impact factor: 3.616

9.  Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission.

Authors:  J J Eron; P L Vernazza; D M Johnston; F Seillier-Moiseiwitsch; T M Alcorn; S A Fiscus; M S Cohen
Journal:  AIDS       Date:  1998-10-22       Impact factor: 4.177

10.  Cross-clade simultaneous HIV drug resistance genotyping for reverse transcriptase, protease, and integrase inhibitor mutations by Illumina MiSeq.

Authors:  Dawn M Dudley; Adam L Bailey; Shruti H Mehta; Austin L Hughes; Gregory D Kirk; Ryan P Westergaard; David H O'Connor
Journal:  Retrovirology       Date:  2014-12-23       Impact factor: 4.602

View more
  7 in total

1.  Low-Abundance Drug-Resistant HIV-1 Variants in Antiretroviral Drug-Naive Individuals: A Systematic Review of Detection Methods, Prevalence, and Clinical Impact.

Authors:  Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner
Journal:  J Infect Dis       Date:  2020-04-27       Impact factor: 5.226

2.  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.

Authors:  Anna Maria Geretti; Ellen White; Chloe Orkin; Anna Tostevin; Peter Tilston; David Chadwick; Clifford Leen; Caroline Sabin; David T Dunn
Journal:  J Antimicrob Chemother       Date:  2019-03-01       Impact factor: 5.790

3.  Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population.

Authors:  Soo-Yon Rhee; Dana Clutter; W Jeffrey Fessel; Daniel Klein; Sally Slome; Benjamin A Pinsky; Julia L Marcus; Leo Hurley; Michael J Silverberg; Sergei L Kosakovsky Pond; Robert W Shafer
Journal:  Clin Infect Dis       Date:  2019-01-07       Impact factor: 9.079

4.  Proliferative memory SAMHD1low CD4+ T cells harbour high levels of HIV-1 with compartmentalized viral populations.

Authors:  Lylia Hani; Antoine Chaillon; Marie-Laure Nere; Nicolas Ruffin; Joudy Alameddine; Maud Salmona; José-Luiz Lopez Zaragoza; Davey M Smith; Olivier Schwartz; Jean-Daniel Lelièvre; Constance Delaugerre; Yves Lévy; Nabila Seddiki
Journal:  PLoS Pathog       Date:  2019-06-20       Impact factor: 6.823

5.  Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction.

Authors:  Jean L Mbisa; Peter Kirwan; Anna Tostevin; Juan Ledesma; David F Bibby; Alison Brown; Richard Myers; Amin S Hassan; Gary Murphy; David Asboe; Anton Pozniak; Stuart Kirk; O Noel Gill; Caroline Sabin; Valerie Delpech; David T Dunn
Journal:  Clin Infect Dis       Date:  2019-09-13       Impact factor: 9.079

6.  Pretreatment HIV drug resistance spread within transmission clusters in Mexico City.

Authors:  Margarita Matías-Florentino; Antoine Chaillon; Santiago Ávila-Ríos; Sanjay R Mehta; Héctor E Paz-Juárez; Manuel A Becerril-Rodríguez; Silvia J Del Arenal-Sánchez; Alicia Piñeirúa-Menéndez; Verónica Ruiz; Patricia Iracheta-Hernández; Israel Macías-González; Jehovani Tena-Sánchez; Florentino Badial-Hernández; Andrea González-Rodríguez; Gustavo Reyes-Terán
Journal:  J Antimicrob Chemother       Date:  2020-03-01       Impact factor: 5.790

7.  Establishment and application of a method of tagged-amplicon deep sequencing for low-abundance drug resistance in HIV-1.

Authors:  Yang Li; Leilei Han; Yanglan Wang; Xiaolin Wang; Lei Jia; Jingyun Li; Jingwan Han; Jin Zhao; Hanping Li; Lin Li
Journal:  Front Microbiol       Date:  2022-08-22       Impact factor: 6.064

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.